NASDAQ:ALNY - Alnylam Pharmaceuticals Stock Price, Forecast & News

Alnylam Pharmaceuticals trades on the NASDAQ under the ticker symbol "ALNY."

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) released its quarterly earnings results on Thursday, February, 6th. The biopharmaceutical company reported ($2.47) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($2.25) by $0.22. The biopharmaceutical company had revenue of $71.70 million for the quarter, compared to the consensus estimate of $71.45 million. Alnylam Pharmaceuticals had a negative net margin of 403.24% and a negative return on equity of 55.82%. Alnylam Pharmaceuticals's revenue for the quarter was up 241.4% compared to the same quarter last year. During the same period last year, the company earned ($1.82) earnings per share. View Alnylam Pharmaceuticals' Earnings History.

Alnylam Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, May 6th 2020. View Earnings Estimates for Alnylam Pharmaceuticals.

17 brokers have issued twelve-month price targets for Alnylam Pharmaceuticals' shares. Their forecasts range from $70.00 to $190.00. On average, they expect Alnylam Pharmaceuticals' stock price to reach $125.71 in the next twelve months. This suggests that the stock has a possible downside of 4.1%. View Analyst Price Targets for Alnylam Pharmaceuticals.

17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alnylam Pharmaceuticals in the last year. There are currently 1 sell rating, 4 hold ratings and 12 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Alnylam Pharmaceuticals.

Media stories about ALNY stock have trended very positive on Sunday, according to InfoTrie Sentiment. InfoTrie identifies positive and negative press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Alnylam Pharmaceuticals earned a media sentiment score of 4.0 on InfoTrie's scale. They also gave press coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the company's share price in the next few days. View News Stories for Alnylam Pharmaceuticals.

Alnylam Pharmaceuticals saw a increase in short interest in January. As of January 31st, there was short interest totalling 4,800,000 shares, an increase of 8.6% from the January 15th total of 4,420,000 shares. Based on an average daily trading volume, of 723,500 shares, the short-interest ratio is currently 6.6 days. Currently, 4.4% of the shares of the company are short sold. View Alnylam Pharmaceuticals' Current Options Chain.

Some companies that are related to Alnylam Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Seattle Genetics (SGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS), Exelixis (EXEL) and Repligen (RGEN).

Based on aggregate information from My MarketBeat watchlists, some companies that other Alnylam Pharmaceuticals investors own include Alibaba Group (BABA), XOMA (XOMA), Ionis Pharmaceuticals (IONS), NVIDIA (NVDA), Gilead Sciences (GILD), NXP Semiconductors (NXPI), Mylan (MYL), Netflix (NFLX), Opko Health (OPK) and Micron Technology (MU).

Alnylam Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional investors include FMR LLC (15.00%), Baillie Gifford & Co. (7.34%), State Street Corp (2.60%), Maverick Capital Ltd. (2.03%), Farallon Capital Management LLC (1.30%) and Geode Capital Management LLC (1.10%). Company insiders that own Alnylam Pharmaceuticals stock include Akshay Vaishnaw, Barry E Greene, John Maraganore, Laurie Keating, Marsha Fanucci, Paul Schimmel, Philip A Sharp, Phillip A Sharp, Steven M Paul and Yvonne Greenstreet. View Institutional Ownership Trends for Alnylam Pharmaceuticals.

ALNY stock was sold by a variety of institutional investors in the last quarter, including Maverick Capital Ltd., Fred Alger Management LLC, First Trust Advisors LP, State Street Corp, Sectoral Asset Management Inc, Casdin Capital LLC, Pictet Asset Management Ltd. and Franklin Resources Inc.. Company insiders that have sold Alnylam Pharmaceuticals company stock in the last year include Akshay Vaishnaw, Barry E Greene, John Maraganore, Laurie Keating, Marsha Fanucci, Philip A Sharp, Phillip A Sharp, Steven M Paul and Yvonne Greenstreet. View Insider Buying and Selling for Alnylam Pharmaceuticals.

ALNY stock was acquired by a variety of institutional investors in the last quarter, including Marshall Wace North America L.P., Bridger Management LLC, Cubist Systematic Strategies LLC, Geode Capital Management LLC, California Public Employees Retirement System, Great West Life Assurance Co. Can, DCF Advisers LLC and FMR LLC. View Insider Buying and Selling for Alnylam Pharmaceuticals.

Shares of ALNY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ALNY stock can currently be purchased for approximately $131.03.

Alnylam Pharmaceuticals has a market capitalization of $14.75 billion and generates $219.75 million in revenue each year. The biopharmaceutical company earns $-886,120,000.00 in net income (profit) each year or ($8.11) on an earnings per share basis. Alnylam Pharmaceuticals employs 1,065 workers across the globe.View Additional Information About Alnylam Pharmaceuticals.

The official website for Alnylam Pharmaceuticals is http://www.alnylam.com/.

Alnylam Pharmaceuticals' mailing address is 675 WEST KENDALL STREET HENRI A. TERMEER SQUARE, CAMBRIDGE MA, 02142. The biopharmaceutical company can be reached via phone at 617-551-8200 or via email at [email protected]